AU2020217659B2 - Methods for treating symptoms and disorders associated with lysosomal storage diseases - Google Patents

Methods for treating symptoms and disorders associated with lysosomal storage diseases Download PDF

Info

Publication number
AU2020217659B2
AU2020217659B2 AU2020217659A AU2020217659A AU2020217659B2 AU 2020217659 B2 AU2020217659 B2 AU 2020217659B2 AU 2020217659 A AU2020217659 A AU 2020217659A AU 2020217659 A AU2020217659 A AU 2020217659A AU 2020217659 B2 AU2020217659 B2 AU 2020217659B2
Authority
AU
Australia
Prior art keywords
compound
subject
halogen
alkyloxy
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020217659A
Other languages
English (en)
Other versions
AU2020217659A1 (en
Inventor
Nigel Patrick Somerville CRAWFORD
Tanya Zaremba FISCHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2020217659A1 publication Critical patent/AU2020217659A1/en
Application granted granted Critical
Publication of AU2020217659B2 publication Critical patent/AU2020217659B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020217659A 2019-02-04 2020-02-03 Methods for treating symptoms and disorders associated with lysosomal storage diseases Active AU2020217659B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962800996P 2019-02-04 2019-02-04
US62/800,996 2019-02-04
US201962851433P 2019-05-22 2019-05-22
US62/851,433 2019-05-22
US201962894167P 2019-08-30 2019-08-30
US62/894,167 2019-08-30
US201962937618P 2019-11-19 2019-11-19
US62/937,618 2019-11-19
US202062962647P 2020-01-17 2020-01-17
US62/962,647 2020-01-17
PCT/US2020/016441 WO2020163245A1 (en) 2019-02-04 2020-02-03 Methods for treating symptoms and disorders associated with lysosomal storage diseases

Publications (2)

Publication Number Publication Date
AU2020217659A1 AU2020217659A1 (en) 2021-08-26
AU2020217659B2 true AU2020217659B2 (en) 2025-04-17

Family

ID=69743942

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020217659A Active AU2020217659B2 (en) 2019-02-04 2020-02-03 Methods for treating symptoms and disorders associated with lysosomal storage diseases
AU2020218496A Active AU2020218496B2 (en) 2019-02-04 2020-02-03 Methods for treating symptoms and disorders associated with lysosomal storage diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020218496A Active AU2020218496B2 (en) 2019-02-04 2020-02-03 Methods for treating symptoms and disorders associated with lysosomal storage diseases

Country Status (13)

Country Link
US (2) US20220016092A1 (cg-RX-API-DMAC7.html)
EP (2) EP3920913A1 (cg-RX-API-DMAC7.html)
JP (3) JP2022520747A (cg-RX-API-DMAC7.html)
KR (2) KR20210123352A (cg-RX-API-DMAC7.html)
CN (2) CN113645969A (cg-RX-API-DMAC7.html)
AU (2) AU2020217659B2 (cg-RX-API-DMAC7.html)
BR (2) BR112021015099A2 (cg-RX-API-DMAC7.html)
CA (1) CA3128039A1 (cg-RX-API-DMAC7.html)
IL (3) IL313808B1 (cg-RX-API-DMAC7.html)
MX (2) MX2021009383A (cg-RX-API-DMAC7.html)
SG (2) SG11202107844UA (cg-RX-API-DMAC7.html)
TW (2) TWI865485B (cg-RX-API-DMAC7.html)
WO (2) WO2020163244A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160207933A1 (en) * 2011-03-18 2016-07-21 Genzyme Corporation Glucosylceramide synthase inhibitors
US20180036295A1 (en) * 2015-03-10 2018-02-08 Genzyme Corporation Methods for treating proteinopathies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (cg-RX-API-DMAC7.html) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
AU2012272815B2 (en) * 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
JO3713B1 (ar) * 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
EP3079695B1 (en) 2013-12-11 2021-03-17 Genzyme Corporation Glucosylceramide synthase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160207933A1 (en) * 2011-03-18 2016-07-21 Genzyme Corporation Glucosylceramide synthase inhibitors
US20180036295A1 (en) * 2015-03-10 2018-02-08 Genzyme Corporation Methods for treating proteinopathies

Also Published As

Publication number Publication date
TW202045168A (zh) 2020-12-16
MX2021009384A (es) 2021-09-10
CA3128041A1 (en) 2020-08-13
TW202508582A (zh) 2025-03-01
IL285304B1 (en) 2025-06-01
AU2020217659A1 (en) 2021-08-26
IL313808B1 (en) 2026-05-01
JP2022519274A (ja) 2022-03-22
SG11202107844UA (en) 2021-08-30
BR112021015099A2 (pt) 2021-10-05
TW202045167A (zh) 2020-12-16
SG11202107842QA (en) 2021-08-30
IL285304B2 (en) 2025-10-01
MX2021009383A (es) 2021-09-10
CA3128039A1 (en) 2020-08-13
IL285187B1 (en) 2026-06-01
US20220016092A1 (en) 2022-01-20
WO2020163245A1 (en) 2020-08-13
AU2020218496B2 (en) 2024-12-19
CN113710249A (zh) 2021-11-26
IL313808A (en) 2024-08-01
KR20210123352A (ko) 2021-10-13
KR20210123353A (ko) 2021-10-13
AU2020218496A1 (en) 2021-08-26
TWI865485B (zh) 2024-12-11
BR112021015172A2 (pt) 2021-09-28
US20220023273A1 (en) 2022-01-27
IL285187A (en) 2021-09-30
EP3920914A1 (en) 2021-12-15
JP7511567B2 (ja) 2024-07-05
JP2022520747A (ja) 2022-04-01
JP2025072556A (ja) 2025-05-09
WO2020163244A1 (en) 2020-08-13
CN113645969A (zh) 2021-11-12
EP3920913A1 (en) 2021-12-15
IL285304A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
AU2021215396B2 (en) Methods for treating neurological symptoms associated with lysosomal storage diseases
JP2025072556A (ja) リソソーム蓄積性疾患と関連する症状および障害を処置するための方法
KR20170123329A (ko) 단백질병증을 치료하기 위한 방법
CA3128041C (en) Methods for treating symptoms and disorders associated with lysosomal storage diseases
RU2824599C2 (ru) Способы лечения симптомов и нарушений, ассоциированных с лизосомными болезнями накопления
RU2829786C2 (ru) Способы лечения симптомов и нарушений, ассоциированных с лизосомными болезнями накопления
RU2839414C1 (ru) Способы лечения неврологических симптомов, ассоциированных с лизосомными болезнями накопления
WO2025219952A1 (en) Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders
WO2025262570A1 (en) Venglustat as an inhibitor of glucosylceramide synthase in subjects having hepatic impairment

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)